



an Open Access Journal by MDPI

## Exploring Biomarkers and Pharmacotherapies for Substance Use Disorders

Guest Editors:

**Dr. Ani Gasparyan**

Institute of Neurosciences, Miguel  
Hernandez University, Alicante,  
Spain

**Dr. Daniela Navarro**

Institute of Neurosciences, Miguel  
Hernandez University, Alicante,  
Spain

**Prof. Dr. Jorge Manzanares**

Instituto de Neurociencias,  
Miguel Hernández University, Av.  
Ramón y Cajal s/n, 03550 San  
Juan de Alicante, Alicante, Spain

Deadline for manuscript  
submissions:

**25 November 2024**

### Message from the Guest Editors

Dear Colleagues,

This is a Special Issue with a focused objective of identifying behavioral, genetic, and epigenetic mechanisms involved in drug addiction, as well as potential new pharmacological agents for treating these disorders in both human and animal models.

Substance Use Disorders (SUD), encompassing alcohol, cannabis, stimulants, and other substances, pose a significant global health burden, impacting millions of people worldwide. Despite the profound consequences of these disorders on individuals, families, and societies, effective and precise diagnostic and therapeutic approaches remain limited. Therefore, it is imperative to identify the specific biomarkers associated with different stages of the disease, aiming to deepen our understanding of the underlying alterations and explore effective pharmacological interventions.

To summarize, we aim to cover all the essential aspects that can contribute to our enhanced comprehension of the biological basis of addiction and the identification of pharmacological interventions for treating SUD.

Dr. Ani Gasparyan

Dr. Daniela Navarro

Prof. Dr. Jorge Manzanares

*Guest Editors*



[mdpi.com/si/181254](https://mdpi.com/si/181254)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)